𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Myo-inositol in the treatment of premenstrual dysphoric disorder

✍ Scribed by Gianfranco Carlomagno; Vittorio Unfer; Silvia Buffo; Francesco D'Ambrosio

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
99 KB
Volume
26
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Objective

Premenstrual dysphoric disorder (PMDD) is a mood disorder disrupting social and/or occupational life of affected women. Premenstrual dysphoric disorder etiology is unknown, although a pivotal role is played by the serotoninergic system. Indeed, one of the most effective treatments is selective serotonin reuptake inhibitors. Several studies have proposed a selective serotonin reuptake inhibitor‐like role for myo‐inositol, likely due to the fact that myo‐inositol is the second messenger of serotonin. In the present study, we aimed to investigate the effect of myo‐inositol in the treatment of PMDD.

Methods

We used a two‐phase clinical trial approach (phase I: placebo washout; phase II: comparisons between treatment and placebo) and treated PMMD patients with two different myo‐inositol formulations: powder or soft gel capsules. We decided to test these two formulations because according to the manufacturer, 0.6 g of myo‐inositol in soft gel capsule has a pharmacokinetic equivalent to 2 g of myo‐inositol in powder.

Results

Our results showed a significant improvement of three different scales: a reduction in the Daily Symptoms Records scale and an improvement of the Hamilton Depression Rating and Clinical Global Impression—Severity of Illness scales. Results were similar for both formulations.

Conclusions

In the present study, by using a new pharmaceutical formulation, we were able to clearly prove the efficacy of myo‐inositol in PMDD. Copyright © 2011 John Wiley & Sons, Ltd.

📜 SIMILAR VOLUMES

Fluoxetine versus Vitex agnus castus ext
Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder
✍ Murad Atmaca; Selahattin Kumru; Ertan Tezcan 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

## Abstract Clinical trials have demonstrated that serotonin reuptake inhibitors (SRIs) and the extract of __Vitex agnus castus__ are effective for the treatment of premenstrual dysphoric disorder (PMDD). However, to the best of our knowledge, there has been no study comparing the efficacy of the S

Lack of beneficial effects of clonidine
Lack of beneficial effects of clonidine in the treatment of premenstrual dysphoric disorder: results of a double-blind, randomized study
✍ Robertas Bunevicius; Alan L. Hinderliter; Kathleen C. Light; Cort A. Pedersen; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Objectives To test the effects of clonidine in comparison with active placebo on premenstrual symptoms, mood scores and norepinephrine (NE) concentration, in women with premenstrual dysphoric disorder (PMDD). Methods Twelve women with prospectively confirmed PMDD were randomly assigned to oral 0.3 m

Myo-inositol enhances teratogenicity of
Myo-inositol enhances teratogenicity of valproic acid in the mouse
✍ Valentina Massa; Bogdan Wlodarczyk; Erminio Giavini; Richard H. Finnell 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB 👁 2 views

## Abstract ## BACKGROUND Valproic acid (VPA) is an anticonvulsant drug that is widely used therapeutically for a variety of neurological conditions. VPA is also well known for its teratogenic potential in both humans and experimental animal models. The typical malformations observed following VPA